Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 04, 2025 19:00 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology

SALT LAKE CITY, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced The Lancet Oncology...
July 02, 2025 08:45 ET | Source: International Myeloma Foundation

The International Myeloma Foundation Proudly Announces EMA-CHMP Positive Qualification Advice to i2TEAMM Novel Biomarker Procedure Application on the Use of MRDnegCR as an Intermediate Early Endpoint for Conditional Market Approval in Myeloma Clinical Trials

STUDIO CITY, Calif., July 02, 2025 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) and the collaborative stakeholder group i2TEAMM (International Independent Team for Endpoint...
June 06, 2025 03:31 ET | Source: Burning Rock Biotech Limited

Burning Rock Reports First Quarter 2025 Financial Results

Burning Rock Reports First Quarter 2025 Financial Results
June 02, 2025 09:00 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Shares New Clinical Data Demonstrating Sensitivity of Precise MRD Across Multiple Cancer Types

SALT LAKE CITY, June 02, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced new molecular residual...
May 27, 2025 16:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting

SALT LAKE CITY, May 27, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will share data from seven new...
April 25, 2025 16:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting

SALT LAKE CITY, April 25, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced new clinical data will be shared...
February 05, 2025 16:15 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay

Myriad Genetics announces it was granted two new patents for its Molecular Residual Disease (MRD) assay.
January 07, 2025 08:00 ET | Source: Myriad Genetics, Inc.

MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay

The University of Texas MD Anderson Cancer Center and Myriad Genetics announced a five-year strategic alliance.
December 10, 2024 08:00 ET | Source: AmMax Bio, Inc.

AmMax Bio and MD Anderson Announce Agreements to Advance Development of AMB-066 in Colorectal Cancer Patients with Minimal Residual Disease

AmMax Bio and MD Anderson to Advance Development of AMB-066 in Colorectal Cancer Patients with Minimal Residual Disease
October 08, 2024 16:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Announces Five Research Collaborations to Study the Use of MRD Testing in Breast Cancer

SALT LAKE CITY, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a series of ongoing research...